Similar articles

• Clinical significance of serum levels of anti-transcriptional intermediary factor 1-γ antibody in patients with dermatomyositis.

  Ikeda N, Yamaguchi Y, Kanaoka M, Ototake Y, Akita A, Watanabe T, Aihara M. Ikeda N, et al. J Dermatol. 2020 May;47(5):490-496. doi: 10.1111/1346-8138.15284. Epub 2020 Feb 27. J Dermatol. 2020. PMID: 32103537
• Anti-transcription intermediary factor 1-γ antibody-positive clinically amyopathic dermatomyositis complicated by interstitial lung disease and breast cancer.

  Ogawa M, Sugiura K, Yokota K, Muro Y, Akiyama M. Ogawa M, et al. J Eur Acad Dermatol Venereol. 2016 Feb;30(2):373-5. doi: 10.1111/jdv.12797. Epub 2014 Oct 23. J Eur Acad Dermatol Venereol. 2016. PMID: 25346167 No abstract available.
• Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.

  Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Hoshino K, et al. Rheumatology (Oxford). 2010 Sep;49(9):1726-33. doi: 10.1093/rheumatology/keq153. Epub 2010 May 25. Rheumatology (Oxford). 2010. PMID: 20501546
• Recent advances in dermatomyositis-specific autoantibodies.

  Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Fujimoto M, et al. Curr Opin Rheumatol. 2016 Nov;28(6):636-44. doi: 10.1097/BOR.0000000000000329. Curr Opin Rheumatol. 2016. PMID: 27533321 Review.
• Amyopathic Dermatomyositis: A Concise Review of Clinical Manifestations and Associated Malignancies.

  Udkoff J, Cohen PR. Udkoff J, et al. Am J Clin Dermatol. 2016 Oct;17(5):509-518. doi: 10.1007/s40257-016-0199-z. Am J Clin Dermatol. 2016. PMID: 27256496 Review.